Loading viewer...
annual_report
Format: PDF annual_report
Acadia Pharmaceuticals reported strong 2020 performance with NUPLAZID net sales of $441.8 million, representing 30% year-over-year growth for treating Parkinson's disease psychosis. The company advanced its neuroscience pipeline including Phase 3 programs in Rett syndrome and schizophrenia negative symptoms, while expanding into pain management through the acquisition of CerSci Therapeutics.
Archer-Daniels-Midland 2018 Proxy Statement Amendment
annual_reportannual_report
209 Pages
Archer Daniels Midland Company
annual_report
Grange Resources
presentation
ADP Annual Report 2018 Form 10-K
annual_reportannual_report
139 Pages
Automatic Data Processing
annual_report
ABB Ltd